Search Results - "Carlos Camps"

Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro by Milian, Lara, Mata, Manuel, Alcacer, Javier, Oliver, María, Sancho-Tello, María, Martín de Llano, José Javier, Camps, Carlos, Galbis, José, Carretero, Julian, Carda, Carmen

“…Patients with non-small cell lung cancer (NSCLC) develop resistance to antitumor agents by mechanisms that involve the epithelial-to-mesenchymal transition…”
Get full text

The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer by Bremnes, Roy M, Dønnem, Tom, Al-Saad, Samer, Al-Shibli, Khalid, Andersen, Sigve, Sirera, Rafael, Camps, Carlos, Marinez, Inigo, Busund, Lill-Tove

“…Maintenance of both normal epithelial tissues and their malignant counterparts is supported by the host tissue stroma. The tumor stroma mainly consists of the…”
Get more information

Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer by Malapelle, Umberto, Sirera, Rafael, Jantus-Lewintre, Eloísa, Reclusa, Pablo, Calabuig-Fariñas, Silvia, Blasco, Ana, Pisapia, Pasquale, Rolfo, Christian, Camps, Carlos

“…The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the development of genome-based personalized medicine. Fifteen to 20% of…”
Get more information

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer by Rosell, Rafael, Moran, Teresa, Queralt, Cristina, Porta, Rut, Cardenal, Felipe, Camps, Carlos, Majem, Margarita, Lopez-Vivanco, Guillermo, Isla, Dolores, Provencio, Mariano, Insa, Amelia, Massuti, Bartomeu, Gonzalez-Larriba, Jose Luis, Paz-Ares, Luis, Bover, Isabel, Garcia-Campelo, Rosario, Moreno, Miguel Angel, Catot, Silvia, Rolfo, Christian, Reguart, Noemi, Palmero, Ramon, Sánchez, José Miguel, Bastus, Roman, Mayo, Clara, Bertran-Alamillo, Jordi, Molina, Miguel Angel, Sanchez, Jose Javier, Taron, Miquel

“…Lung cancers with a mutation in the EGFR gene have heightened sensitivity to tyrosine kinase inhibitors. Asian patients have been the most intensively studied…”
Get full text

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer by García-Foncillas, Jesús, Tabernero, Josep, Élez, Elena, Aranda, Enrique, Benavides, Manuel, Camps, Carlos, Jantus-Lewintre, Eloisa, López, Rafael, Muinelo-Romay, Laura, Montagut, Clara, Antón, Antonio, López, Guillermo, Díaz-Rubio, Eduardo, Rojo, Federico, Vivancos, Ana

“…Background Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was…”
Get full text

Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer by Núñez Abad, Martín, Calabuig-Fariñas, Silvia, Lobo de Mena, Miriam, Torres-Martínez, Susana, García González, Clara, García García, José Ángel, Iranzo González-Cruz, Vega, Camps Herrero, Carlos

“…Breast cancer constitutes the most common malignant neoplasm in women around the world. Approximately 12% of patients are diagnosed with metastatic stage, and…”
Get full text

Reflections on the Origin of Coded Protein Biosynthesis by Fontecilla-Camps, Juan Carlos

“…The principle of continuity posits that some central features of primordial biocatalytic mechanisms should still be present in the genetically dependent…”
Get full text

The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer by Bremnes, Roy M, Al-Shibli, Khalid, Donnem, Tom, Sirera, Rafael, Al-Saad, Samer, Andersen, Sigve, Stenvold, Helge, Camps, Carlos, Busund, Lill-Tove

“…In addition to malignant neoplastic cells, cancer tissues also include immune cells, fibroblasts, and endothelial cells, including an abundant collection of…”
Get more information

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations by Aapro, Matti, Boccia, Ralph, Leonard, Robert, Camps, Carlos, Campone, Mario, Choquet, Sylvain, Danova, Marco, Glaspy, John, Hus, Iwona, Link, Hartmut, Sliwa, Thamer, Tesch, Hans, Valero, Vicente

“…Purpose Chemotherapy-induced febrile neutropenia (FN) causes treatment delays and interruptions and can have fatal consequences. Current guidelines provide…”
Get full text

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial by Rosell, Rafael, Prof, Dafni, Urania, Prof, Felip, Enriqueta, MD, Curioni-Fontecedro, Alessandra, MD, Gautschi, Oliver, MD, Peters, Solange, MD, Massutí, Bartomeu, MD, Palmero, Ramon, MD, Aix, Santiago Ponce, MD, Carcereny, Enric, MD, Früh, Martin, MD, Pless, Miklos, MD, Popat, Sanjay, FRCP, Kotsakis, Athanasios, MD, Cuffe, Sinead, MD, Bidoli, Paolo, MD, Favaretto, Adolfo, MD, Froesch, Patrizia, MD, Reguart, Noemí, MD, Puente, Javier, MD, Coate, Linda, MD, Barlesi, Fabrice, Prof, Rauch, Daniel, MD, Thomas, Michael, Prof, Camps, Carlos, MD, Gómez-Codina, Jose, MD, Majem, Margarita, MD, Porta, Rut, MD, Shah, Riyaz, FRCP, Hanrahan, Emer, MRCPI, Kammler, Roswitha, BA, Ruepp, Barbara, PharmD, Rabaglio, Manuela, MD, Kassapian, Marie, MSc, Karachaliou, Niki, MD, Tam, Rachel, BSc, Shames, David S, PhD, Molina-Vila, Miguel A, PhD, Stahel, Rolf A, Dr

“…Summary Background The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring…”
Get full text

Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer by FELIP, Enriqueta, ROSELL, Rafael, CAMPS, Carlos, GUIJARRO, Ricardo, ISLA, Dolores, AGUILO, Rafael, ALBEROLA, Vicente, PADILLA, José, SANCHEZ-PALENCIA, Abel, SANCHEZ, José Javier, HERMOSILLA, Eduardo, MASSUTI, Bartomeu, MAESTRE, José Antonio, RODRIGUEZ-PANIAGUA, José Manuel, MORAN, Teresa, ASTUDILLO, Julio, ALONSO, Guillermo, BORRO, José Manuel, GONZALEZ-LARRIBA, José Luis, TORRES, Antonio

“…To address whether preoperative chemotherapy plus surgery or surgery plus adjuvant chemotherapy prolongs disease-free survival compared with surgery alone…”
Get full text

Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer by AJONA, Daniel, PAJARES, María J, CAMPS, Carlos, ZULUETA, Javier J, MONTUENGA, Luis M, PIO, Ruben, CORRALES, Leticia, PEREZ-GRACIA, Jose L, AGORRETA, Jackeline, LOZANO, Maria D, TORRE, Wenceslao, MASSION, Pierre P, DE-TORRES, Juan P, JANTUS-LEWINTRE, Eloisa

“…There is a medical need for diagnostic biomarkers in lung cancer. We evaluated the diagnostic performance of complement activation fragments. We assessed…”
Get full text

Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer by Torres-Martínez, Susana, Calabuig-Fariñas, Silvia, Gallach, Sandra, Mosqueda, Marais, Munera-Maravilla, Ester, Sirera, Rafael, Navarro, Lara, Blasco, Ana, Camps, Carlos, Jantus-Lewintre, Eloisa

“…Immunotherapy has been proven a viable treatment option for non-small cell lung cancer (NSCLC) treatment in patients. However, some patients still do not…”
Get full text

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer by COBO, Manuel, ISLA, Dolores, FELIP, Enriqueta, ALBEROLA, Vicente, CAMPS, Carlos, DOMINE, Manuel, SANCHEZ, Jose Javier, SANCHEZ-RONCO, Maria, DANENBERG, Kathleen, TARON, Miquel, GANDARA, David, ROSELL, Rafael, MASSUTI, Bartomeu, MONTES, Ana, SANCHEZ, Jose Miguel, PROVENCIO, Mariano, VINOLAS, Nuria, PAZ-ARES, Luis, LOPEZ-VIVANCO, Guillermo, MUNOZ, Miguel Angel

“…Although current treatment options for metastatic non-small-cell lung cancer (NSCLC) rely on cisplatin-based chemotherapy, individualized approaches to therapy…”
Get full text

MicroRNAs : Promising New Antiangiogenic Targets in Cancer by Gallach, Sandra, Calabuig-Fariñas, Silvia, Jantus-Lewintre, Eloisa, Camps, Carlos

“…MicroRNAs are one class of small, endogenous, non-coding RNAs that are approximately 22 nucleotides in length; they are very numerous, have been…”
Get full text

Soluble galectin‐3 as a microenvironment‐relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma by Torres‐Martínez, Susana, Calabuig‐Fariñas, Silvia, Moreno‐Manuel, Andrea, Bertolini, Giulia, Herreros‐Pomares, Alejandro, Escorihuela, Eva, Duréndez‐Saéz, Elena, Guijarro, Ricardo, Blasco, Ana, Roz, Luca, Camps, Carlos, Jantus‐Lewintre, Eloisa

“…Despite the success of therapies in lung cancer, more studies of new biomarkers for patient selection are urgently needed. The present study aims to analyze…”
Get full text

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics by Provencio, Mariano, Cobo, Manuel, Rodriguez-Abreu, Delvys, Calvo, Virginia, Carcereny, Enric, Cantero, Alexandra, Bernabé, Reyes, Benitez, Gretel, Castro, Rafael López, Massutí, Bartomeu, del Barco, Edel, García Campelo, Rosario, Guirado, Maria, Camps, Carlos, Ortega, Ana Laura, González Larriba, Jose Luis, Sánchez, Alfredo, Casal, Joaquín, Sala, M. Angeles, Juan-Vidal, Oscar, Bosch-Barrera, Joaquim, Oramas, Juana, Dómine, Manuel, Trigo, Jose Manuel, Blanco, Remei, Calzas, Julia, Morilla, Idoia, Padilla, Airam, Pimentao, Joao, Sousa, Pedro A, Torrente, Maria

“…Background The survival of patients with lung cancer has substantially increased in the last decade by about 15%. This increase is, basically, due to targeted…”
Get full text

Update on systemic treatment in early triple negative breast cancer by Núñez Abad, Martín, Calabuig-Fariñas, Silvia, Lobo de Mena, Miriam, José Godes Sanz de Bremond, María, García González, Clara, Torres Martínez, Susana, García-García, José Ángel, Iranzo González-Cruz, Vega, Camps Herrero, Carlos

“…Triple negative breast cancer (TNBC) is a heterogeneous disease representing about 15% of all breast cancers. TNBC are usually high-grade histological tumors,…”
Get full text

Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts by Camps Herrero, Carlos, Antón Torres, Antonio, Cruz-Hernández, Juan Jesús, Carrato, Alfredo, Constenla, Manuel, Díaz-Rubio, Eduardo, Feyjoo Saus, Margarita, Garcia-Foncillas, Jesus, Gascón, Pere, Guillem, Vicente

“…There is a lack of standards for the diagnosis, assessment and management of breakthrough cancer pain (BTcP). La Fundación ECO (the Foundation for Excellence…”
Get full text

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data by Gutiérrez, Lourdes, Royuela, Ana, Carcereny, Enric, López-Castro, Rafael, Rodríguez-Abreu, Delvys, Massuti, Bartomeu, González-Larriba, José Luis, García-Campelo, Rosario, Bosch-Barrera, Joaquim, Guirado, María, Camps, Carlos, Dómine, Manuel, Bernabé, Reyes, Casal, Joaquín, Oramas, Juana, Ortega, Ana Laura, Sala, Mª Angeles, Padilla, Airam, Aguiar, David, Juan-Vidal, Oscar, Blanco, Remei, Del Barco, Edel, Martínez-Banaclocha, Natividad, Benítez, Gretel, de Vega, Blanca, Hernández, Ainhoa, Saigi, Maria, Franco, Fernando, Provencio, Mariano

“…There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops a prognostic model using real…”
Get full text